81 reports of this reaction
3.0% of all PETROLATUM reports
#2 most reported adverse reaction
RASH is the #2 most commonly reported adverse reaction for PETROLATUM, manufactured by Aldermed Inc.. There are 81 FDA adverse event reports linking PETROLATUM to RASH. This represents approximately 3.0% of all 2,672 adverse event reports for this drug.
Patients taking PETROLATUM who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH is a less commonly reported adverse event for PETROLATUM, but still significant enough to appear in the safety profile.
In addition to rash, the following adverse reactions have been reported for PETROLATUM:
The following drugs have also been linked to rash in FDA adverse event reports:
RASH has been reported as an adverse event in 81 FDA reports for PETROLATUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH accounts for approximately 3.0% of all adverse event reports for PETROLATUM, making it one of the most commonly reported side effect.
If you experience rash while taking PETROLATUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.